Novo Nordisk’s Wegovy cut cardiovascular risks significantly versus tirzepatide in a real-world study, showing fewer heart attacks, strokes, and deaths.
Novo Nordisk’s Wegovy Outshines Eli Lilly’s Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death
